Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome
In this multicentre, randomized, double-blind, controlled, parallel-group trial, 103 patients with type 2 diabetes mellitus and metabolic syndrome were randomized to receive one of two thiazolidinediones – pioglitazone or rosiglitazone – in combination with 1500 mg/day of metformin, increasing up to...
Gespeichert in:
| Veröffentlicht in: | Journal of international medical research 2006-09, Vol.34 (5), p.545-555 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 555 |
|---|---|
| container_issue | 5 |
| container_start_page | 545 |
| container_title | Journal of international medical research |
| container_volume | 34 |
| creator | Derosa, G D'Angelo, A Ragonesi, PD Ciccarelli, L Piccinni, MN Pricolo, F Salvadeo, S Montagna, L Gravina, A Ferrari, I Galli, S Paniga, S Cicero, AFG |
| description | In this multicentre, randomized, double-blind, controlled, parallel-group trial, 103 patients with type 2 diabetes mellitus and metabolic syndrome were randomized to receive one of two thiazolidinediones – pioglitazone or rosiglitazone – in combination with 1500 mg/day of metformin, increasing up to 3000 mg/day, for 12 months. Anthropometric, metabolic, coagulation and fibrinolysis parameters were assessed at baseline and after 3, 6, 9 and 12 months. Significant decreases in glycosylated haemoglobin, fasting plasma glucose and post-prandial plasma glucose levels were seen after 9 and 12 months in both groups, and significant decreases in fasting plasma insulin and post-prandial plasma insulin levels were seen after 12 months in both groups. In both groups, improvement in the homeostasis model assessment index compared with baseline was obtained only after 12 months. Plasminogen activator inhibitor-1 levels were significantly lower in both groups after 12 months compared with baseline values. In patients with type 2 diabetes mellitus and metabolic syndrome, the combination of metformin plus thiazolidinediones improved glycaemic control and produced a slight but significant reduction in plasminogen activator inhibitor-1 levels. |
| doi_str_mv | 10.1177/147323000603400513 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_68200339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_147323000603400513</sage_id><sourcerecordid>68200339</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-9d6e4993d22aaaf91dcaca87c531f86a9f1a4401c59322812c68e7a36c8cb633</originalsourceid><addsrcrecordid>eNp9kUtrGzEUhUVJaNy0f6CLolV2k-gxz2Vx8ygkxCTeD3c0V7aCR3IlDcH5L_2v0diGLApdXTg657tXHEK-c3bJeVVd8bySQjLGSiZzxgouP5HZJGaTekJmLI0svRZn5EsIL4zloizEZ3LGKy5lVRcz8vdaa1QxUKfpkwtmtTER3pxFCranC-M-hLkbOmOxp68mrukDRu38YCx1lsY10oV3ce2Tx0Wj6HOEiBN0AdGgTQv2qeVui1TQXwY6jBgSZZP4Y9hvS0jo3GZK72yfUPiVnGrYBPx2nOdkeXO9nN9l94-3v-c_7zMlcx6zpi8xbxrZCwEAuuG9AgV1pQrJdV1CoznkOeOqaKQQNReqrLECWapadaWU5-TigN1692fEENvBBJVOA4tuDG1ZC8akbJJRHIzKuxA86nbrzQB-13LWTp20_3aSQj-O9LEbsP-IHEtIhquDIcAK2xc3eps--z_kO3g9loY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68200339</pqid></control><display><type>article</type><title>Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome</title><source>Sage Journals GOLD Open Access 2024</source><creator>Derosa, G ; D'Angelo, A ; Ragonesi, PD ; Ciccarelli, L ; Piccinni, MN ; Pricolo, F ; Salvadeo, S ; Montagna, L ; Gravina, A ; Ferrari, I ; Galli, S ; Paniga, S ; Cicero, AFG</creator><creatorcontrib>Derosa, G ; D'Angelo, A ; Ragonesi, PD ; Ciccarelli, L ; Piccinni, MN ; Pricolo, F ; Salvadeo, S ; Montagna, L ; Gravina, A ; Ferrari, I ; Galli, S ; Paniga, S ; Cicero, AFG</creatorcontrib><description>In this multicentre, randomized, double-blind, controlled, parallel-group trial, 103 patients with type 2 diabetes mellitus and metabolic syndrome were randomized to receive one of two thiazolidinediones – pioglitazone or rosiglitazone – in combination with 1500 mg/day of metformin, increasing up to 3000 mg/day, for 12 months. Anthropometric, metabolic, coagulation and fibrinolysis parameters were assessed at baseline and after 3, 6, 9 and 12 months. Significant decreases in glycosylated haemoglobin, fasting plasma glucose and post-prandial plasma glucose levels were seen after 9 and 12 months in both groups, and significant decreases in fasting plasma insulin and post-prandial plasma insulin levels were seen after 12 months in both groups. In both groups, improvement in the homeostasis model assessment index compared with baseline was obtained only after 12 months. Plasminogen activator inhibitor-1 levels were significantly lower in both groups after 12 months compared with baseline values. In patients with type 2 diabetes mellitus and metabolic syndrome, the combination of metformin plus thiazolidinediones improved glycaemic control and produced a slight but significant reduction in plasminogen activator inhibitor-1 levels.</description><identifier>ISSN: 0300-0605</identifier><identifier>EISSN: 1473-2300</identifier><identifier>DOI: 10.1177/147323000603400513</identifier><identifier>PMID: 17133785</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Blood Glucose - analysis ; Blood Glucose - drug effects ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - pharmacology ; Male ; Metabolic Syndrome - blood ; Metabolic Syndrome - complications ; Metabolic Syndrome - drug therapy ; Metformin - administration & dosage ; Metformin - pharmacology ; Middle Aged ; Plasminogen Activator Inhibitor 1 - blood ; Thiazolidinediones - administration & dosage ; Thiazolidinediones - pharmacology ; Thrombophilia - drug therapy ; Treatment Outcome</subject><ispartof>Journal of international medical research, 2006-09, Vol.34 (5), p.545-555</ispartof><rights>2006 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c341t-9d6e4993d22aaaf91dcaca87c531f86a9f1a4401c59322812c68e7a36c8cb633</citedby><cites>FETCH-LOGICAL-c341t-9d6e4993d22aaaf91dcaca87c531f86a9f1a4401c59322812c68e7a36c8cb633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/147323000603400513$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/147323000603400513$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21965,27852,27923,27924,44944,45332</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/147323000603400513?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17133785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Derosa, G</creatorcontrib><creatorcontrib>D'Angelo, A</creatorcontrib><creatorcontrib>Ragonesi, PD</creatorcontrib><creatorcontrib>Ciccarelli, L</creatorcontrib><creatorcontrib>Piccinni, MN</creatorcontrib><creatorcontrib>Pricolo, F</creatorcontrib><creatorcontrib>Salvadeo, S</creatorcontrib><creatorcontrib>Montagna, L</creatorcontrib><creatorcontrib>Gravina, A</creatorcontrib><creatorcontrib>Ferrari, I</creatorcontrib><creatorcontrib>Galli, S</creatorcontrib><creatorcontrib>Paniga, S</creatorcontrib><creatorcontrib>Cicero, AFG</creatorcontrib><title>Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome</title><title>Journal of international medical research</title><addtitle>J Int Med Res</addtitle><description>In this multicentre, randomized, double-blind, controlled, parallel-group trial, 103 patients with type 2 diabetes mellitus and metabolic syndrome were randomized to receive one of two thiazolidinediones – pioglitazone or rosiglitazone – in combination with 1500 mg/day of metformin, increasing up to 3000 mg/day, for 12 months. Anthropometric, metabolic, coagulation and fibrinolysis parameters were assessed at baseline and after 3, 6, 9 and 12 months. Significant decreases in glycosylated haemoglobin, fasting plasma glucose and post-prandial plasma glucose levels were seen after 9 and 12 months in both groups, and significant decreases in fasting plasma insulin and post-prandial plasma insulin levels were seen after 12 months in both groups. In both groups, improvement in the homeostasis model assessment index compared with baseline was obtained only after 12 months. Plasminogen activator inhibitor-1 levels were significantly lower in both groups after 12 months compared with baseline values. In patients with type 2 diabetes mellitus and metabolic syndrome, the combination of metformin plus thiazolidinediones improved glycaemic control and produced a slight but significant reduction in plasminogen activator inhibitor-1 levels.</description><subject>Blood Glucose - analysis</subject><subject>Blood Glucose - drug effects</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Male</subject><subject>Metabolic Syndrome - blood</subject><subject>Metabolic Syndrome - complications</subject><subject>Metabolic Syndrome - drug therapy</subject><subject>Metformin - administration & dosage</subject><subject>Metformin - pharmacology</subject><subject>Middle Aged</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Thiazolidinediones - administration & dosage</subject><subject>Thiazolidinediones - pharmacology</subject><subject>Thrombophilia - drug therapy</subject><subject>Treatment Outcome</subject><issn>0300-0605</issn><issn>1473-2300</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtrGzEUhUVJaNy0f6CLolV2k-gxz2Vx8ygkxCTeD3c0V7aCR3IlDcH5L_2v0diGLApdXTg657tXHEK-c3bJeVVd8bySQjLGSiZzxgouP5HZJGaTekJmLI0svRZn5EsIL4zloizEZ3LGKy5lVRcz8vdaa1QxUKfpkwtmtTER3pxFCranC-M-hLkbOmOxp68mrukDRu38YCx1lsY10oV3ce2Tx0Wj6HOEiBN0AdGgTQv2qeVui1TQXwY6jBgSZZP4Y9hvS0jo3GZK72yfUPiVnGrYBPx2nOdkeXO9nN9l94-3v-c_7zMlcx6zpi8xbxrZCwEAuuG9AgV1pQrJdV1CoznkOeOqaKQQNReqrLECWapadaWU5-TigN1692fEENvBBJVOA4tuDG1ZC8akbJJRHIzKuxA86nbrzQB-13LWTp20_3aSQj-O9LEbsP-IHEtIhquDIcAK2xc3eps--z_kO3g9loY</recordid><startdate>20060901</startdate><enddate>20060901</enddate><creator>Derosa, G</creator><creator>D'Angelo, A</creator><creator>Ragonesi, PD</creator><creator>Ciccarelli, L</creator><creator>Piccinni, MN</creator><creator>Pricolo, F</creator><creator>Salvadeo, S</creator><creator>Montagna, L</creator><creator>Gravina, A</creator><creator>Ferrari, I</creator><creator>Galli, S</creator><creator>Paniga, S</creator><creator>Cicero, AFG</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060901</creationdate><title>Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome</title><author>Derosa, G ; D'Angelo, A ; Ragonesi, PD ; Ciccarelli, L ; Piccinni, MN ; Pricolo, F ; Salvadeo, S ; Montagna, L ; Gravina, A ; Ferrari, I ; Galli, S ; Paniga, S ; Cicero, AFG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-9d6e4993d22aaaf91dcaca87c531f86a9f1a4401c59322812c68e7a36c8cb633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Blood Glucose - analysis</topic><topic>Blood Glucose - drug effects</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Male</topic><topic>Metabolic Syndrome - blood</topic><topic>Metabolic Syndrome - complications</topic><topic>Metabolic Syndrome - drug therapy</topic><topic>Metformin - administration & dosage</topic><topic>Metformin - pharmacology</topic><topic>Middle Aged</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Thiazolidinediones - administration & dosage</topic><topic>Thiazolidinediones - pharmacology</topic><topic>Thrombophilia - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Derosa, G</creatorcontrib><creatorcontrib>D'Angelo, A</creatorcontrib><creatorcontrib>Ragonesi, PD</creatorcontrib><creatorcontrib>Ciccarelli, L</creatorcontrib><creatorcontrib>Piccinni, MN</creatorcontrib><creatorcontrib>Pricolo, F</creatorcontrib><creatorcontrib>Salvadeo, S</creatorcontrib><creatorcontrib>Montagna, L</creatorcontrib><creatorcontrib>Gravina, A</creatorcontrib><creatorcontrib>Ferrari, I</creatorcontrib><creatorcontrib>Galli, S</creatorcontrib><creatorcontrib>Paniga, S</creatorcontrib><creatorcontrib>Cicero, AFG</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of international medical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Derosa, G</au><au>D'Angelo, A</au><au>Ragonesi, PD</au><au>Ciccarelli, L</au><au>Piccinni, MN</au><au>Pricolo, F</au><au>Salvadeo, S</au><au>Montagna, L</au><au>Gravina, A</au><au>Ferrari, I</au><au>Galli, S</au><au>Paniga, S</au><au>Cicero, AFG</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome</atitle><jtitle>Journal of international medical research</jtitle><addtitle>J Int Med Res</addtitle><date>2006-09-01</date><risdate>2006</risdate><volume>34</volume><issue>5</issue><spage>545</spage><epage>555</epage><pages>545-555</pages><issn>0300-0605</issn><eissn>1473-2300</eissn><abstract>In this multicentre, randomized, double-blind, controlled, parallel-group trial, 103 patients with type 2 diabetes mellitus and metabolic syndrome were randomized to receive one of two thiazolidinediones – pioglitazone or rosiglitazone – in combination with 1500 mg/day of metformin, increasing up to 3000 mg/day, for 12 months. Anthropometric, metabolic, coagulation and fibrinolysis parameters were assessed at baseline and after 3, 6, 9 and 12 months. Significant decreases in glycosylated haemoglobin, fasting plasma glucose and post-prandial plasma glucose levels were seen after 9 and 12 months in both groups, and significant decreases in fasting plasma insulin and post-prandial plasma insulin levels were seen after 12 months in both groups. In both groups, improvement in the homeostasis model assessment index compared with baseline was obtained only after 12 months. Plasminogen activator inhibitor-1 levels were significantly lower in both groups after 12 months compared with baseline values. In patients with type 2 diabetes mellitus and metabolic syndrome, the combination of metformin plus thiazolidinediones improved glycaemic control and produced a slight but significant reduction in plasminogen activator inhibitor-1 levels.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>17133785</pmid><doi>10.1177/147323000603400513</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0300-0605 |
| ispartof | Journal of international medical research, 2006-09, Vol.34 (5), p.545-555 |
| issn | 0300-0605 1473-2300 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68200339 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Blood Glucose - analysis Blood Glucose - drug effects Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Drug Therapy, Combination Female Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacology Male Metabolic Syndrome - blood Metabolic Syndrome - complications Metabolic Syndrome - drug therapy Metformin - administration & dosage Metformin - pharmacology Middle Aged Plasminogen Activator Inhibitor 1 - blood Thiazolidinediones - administration & dosage Thiazolidinediones - pharmacology Thrombophilia - drug therapy Treatment Outcome |
| title | Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T03%3A20%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Rosiglitazone%20and%20Pioglitazone%20Combined%20with%20Metformin%20on%20the%20Prothrombotic%20State%20of%20Patients%20with%20Type%202%20Diabetes%20Mellitus%20and%20Metabolic%20Syndrome&rft.jtitle=Journal%20of%20international%20medical%20research&rft.au=Derosa,%20G&rft.date=2006-09-01&rft.volume=34&rft.issue=5&rft.spage=545&rft.epage=555&rft.pages=545-555&rft.issn=0300-0605&rft.eissn=1473-2300&rft_id=info:doi/10.1177/147323000603400513&rft_dat=%3Cproquest_AFRWT%3E68200339%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68200339&rft_id=info:pmid/17133785&rft_sage_id=10.1177_147323000603400513&rfr_iscdi=true |